268 related articles for article (PubMed ID: 17229505)
1. Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges.
Fogg CN; Americo JL; Lustig S; Huggins JW; Smith SK; Damon I; Resch W; Earl PL; Klinman DM; Moss B
Vaccine; 2007 Apr; 25(15):2787-99. PubMed ID: 17229505
[TBL] [Abstract][Full Text] [Related]
2. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions.
Fogg C; Lustig S; Whitbeck JC; Eisenberg RJ; Cohen GH; Moss B
J Virol; 2004 Oct; 78(19):10230-7. PubMed ID: 15367588
[TBL] [Abstract][Full Text] [Related]
3. A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge.
Buchman GW; Cohen ME; Xiao Y; Richardson-Harman N; Silvera P; DeTolla LJ; Davis HL; Eisenberg RJ; Cohen GH; Isaacs SN
Vaccine; 2010 Sep; 28(40):6627-36. PubMed ID: 20659519
[TBL] [Abstract][Full Text] [Related]
4. Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge.
Lustig S; Fogg C; Whitbeck JC; Eisenberg RJ; Cohen GH; Moss B
J Virol; 2005 Nov; 79(21):13454-62. PubMed ID: 16227266
[TBL] [Abstract][Full Text] [Related]
5. A Nucleic Acid-Based Orthopoxvirus Vaccine Targeting the Vaccinia Virus L1, A27, B5, and A33 Proteins Protects Rabbits against Lethal Rabbitpox Virus Aerosol Challenge.
Mucker EM; Golden JW; Hammerbeck CD; Kishimori JM; Royals M; Joselyn MD; Ballantyne J; Nalca A; Hooper JW
J Virol; 2022 Feb; 96(3):e0150421. PubMed ID: 34851148
[TBL] [Abstract][Full Text] [Related]
6. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost.
Xiao Y; Aldaz-Carroll L; Ortiz AM; Whitbeck JC; Alexander E; Lou H; Davis HL; Braciale TJ; Eisenberg RJ; Cohen GH; Isaacs SN
Vaccine; 2007 Jan; 25(7):1214-24. PubMed ID: 17098336
[TBL] [Abstract][Full Text] [Related]
7. Protection of Mice from Lethal Vaccinia Virus Infection by Vaccinia Virus Protein Subunits with a CpG Adjuvant.
Reeman S; Gates AJ; Pulford DJ; Krieg A; Ulaeto DO
Viruses; 2017 Dec; 9(12):. PubMed ID: 29232844
[TBL] [Abstract][Full Text] [Related]
8. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice.
Davies DH; McCausland MM; Valdez C; Huynh D; Hernandez JE; Mu Y; Hirst S; Villarreal L; Felgner PL; Crotty S
J Virol; 2005 Sep; 79(18):11724-33. PubMed ID: 16140750
[TBL] [Abstract][Full Text] [Related]
9. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
Berhanu A; Wilson RL; Kirkwood-Watts DL; King DS; Warren TK; Lund SA; Brown LL; Krupkin AK; Vandermay E; Weimers W; Honeychurch KM; Grosenbach DW; Jones KF; Hruby DE
J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
[TBL] [Abstract][Full Text] [Related]
10. Short-term, but not post-exposure, protection against lethal orthopoxvirus challenge after immunization with modified vaccinia virus Ankara.
Staib C; Suezer Y; Kisling S; Kalinke U; Sutter G
J Gen Virol; 2006 Oct; 87(Pt 10):2917-2921. PubMed ID: 16963750
[TBL] [Abstract][Full Text] [Related]
11. Active vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response.
Paran N; Lustig S; Zvi A; Erez N; Israely T; Melamed S; Politi B; Ben-Nathan D; Schneider P; Lachmi B; Israeli O; Stein D; Levin R; Olshevsky U
Virol J; 2013 Jul; 10():229. PubMed ID: 23842430
[TBL] [Abstract][Full Text] [Related]
12. Structural and Functional Characterization of Anti-A33 Antibodies Reveal a Potent Cross-Species Orthopoxviruses Neutralizer.
Matho MH; Schlossman A; Meng X; Benhnia MR; Kaever T; Buller M; Doronin K; Parker S; Peters B; Crotty S; Xiang Y; Zajonc DM
PLoS Pathog; 2015 Sep; 11(9):e1005148. PubMed ID: 26325270
[TBL] [Abstract][Full Text] [Related]
13. Adsorption of recombinant poxvirus L1-protein to aluminum hydroxide/CpG vaccine adjuvants enhances immune responses and protection of mice from vaccinia virus challenge.
Xiao Y; Zeng Y; Alexander E; Mehta S; Joshi SB; Buchman GW; Volkin DB; Middaugh CR; Isaacs SN
Vaccine; 2013 Jan; 31(2):319-26. PubMed ID: 23153450
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and protective efficacy of recombinant major envelope protein (rH3L) of buffalopox virus in animal models.
Kumar A; Yogisharadhya R; Venkatesan G; Bhanuprakash V; Shivachandra SB
Antiviral Res; 2016 Feb; 126():108-16. PubMed ID: 26723250
[TBL] [Abstract][Full Text] [Related]
15. Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.
Golden JW; Zaitseva M; Kapnick S; Fisher RW; Mikolajczyk MG; Ballantyne J; Golding H; Hooper JW
Virol J; 2011 Sep; 8():441. PubMed ID: 21933385
[TBL] [Abstract][Full Text] [Related]
16. Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate.
Earl PL; Americo JL; Wyatt LS; Eller LA; Montefiori DC; Byrum R; Piatak M; Lifson JD; Amara RR; Robinson HL; Huggins JW; Moss B
Virology; 2007 Sep; 366(1):84-97. PubMed ID: 17499326
[TBL] [Abstract][Full Text] [Related]
17. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge.
Pulford DJ; Gates A; Bridge SH; Robinson JH; Ulaeto D
Vaccine; 2004 Sep; 22(25-26):3358-66. PubMed ID: 15308360
[TBL] [Abstract][Full Text] [Related]
18. Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge.
Fogg CN; Americo JL; Earl PL; Resch W; Aldaz-Carroll L; Eisenberg RJ; Cohen GH; Moss B
J Virol; 2008 Aug; 82(16):8022-9. PubMed ID: 18524827
[TBL] [Abstract][Full Text] [Related]
19. Short-term and longer-term protective immune responses generated by subunit vaccination with smallpox A33, B5, L1 or A27 proteins adjuvanted with aluminum hydroxide and CpG in mice challenged with vaccinia virus.
Xiao Y; Zeng Y; Schante C; Joshi SB; Buchman GW; Volkin DB; Middaugh CR; Isaacs SN
Vaccine; 2020 Aug; 38(38):6007-6018. PubMed ID: 32741672
[TBL] [Abstract][Full Text] [Related]
20. Protection induced in mice against a lethal orthopox virus by the Lister strain of vaccinia virus and modified vaccinia virus Ankara (MVA).
Abdalrhman I; Gurt I; Katz E
Vaccine; 2006 May; 24(19):4152-60. PubMed ID: 16603280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
